Connect with us

Technology

Dualitas Therapeutics Announces Proximity Biology Research Collaboration with Roche to Discover and Develop Novel Bispecific Antibodies for I&I Diseases

Published

on

Dualitas will use its DualScreen™ Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations for Immunology & Inflammation (I&I) diseases – representing one of the largest-scale bispecific discovery endeavors Collaboration leverages Dualitas’ proximity biology expertise to discover bispecific antibody therapeutics Dualitas to receive $36.5 million in upfront payments and is eligible to receive research, development and commercial milestone payments and tiered royalties for a potential total deal value of up to $1 billion

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 /PRNewswire/ — Dualitas Therapeutics, Inc., a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammation (“I&I”) indications, today announced a research collaboration and license agreement with Roche to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases, using Dualitas’ DualScreen™ Bispecific Discovery Engine. In what is believed to be one of the largest-scale bispecific discovery endeavors, Dualitas will functionally screen over 300,000 novel bispecific combinations to discover and develop bispecific antibody (“BsAb”) therapeutics. Roche will be responsible for all subsequent preclinical development, regulatory, manufacturing and commercial activities.

The collaboration will leverage Dualitas’ expertise in proximity biology to develop BsAb candidates with synergistic activities that are unattainable with conventional therapeutics. Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for a potential total deal value of up to $1 billion, in addition to tiered royalties.

“We are thrilled to partner with Roche on this first-of-its-kind collaboration to functionally screen and develop novel proximity BsAbs at a scale that was previously unachievable,” said Forbes Huang, co-founder, chief operating officer and chief business officer of Dualitas. “Since founding Dualitas in 2023, we have established our DualScreen™ discovery engine as the premier technology for discovering next-generation proximity BsAbs, as exemplified by our robust therapeutic pipeline entering clinic next year for I&I diseases.”

“Bispecific antibodies remain central to Roche’s portfolio strategy across many disease areas,” said Boris L. Zaïtra, Head of Corporate Business Development at Roche. “We are committed to continue pushing the boundaries of scientific innovation in immunology and inflammation diseases that will ultimately benefit patients through external partnerships.” 

“This collaboration with Roche underscores the enormous potential of Dualitas’ technologies to identify BsAbs that harness novel proximity mechanisms that may deliver truly differentiated results to patients,” said Karim Dabbagh, Ph.D., CEO and board member of Dualitas. “Our internal pipeline of proximity engager BsAbs has already demonstrated the ability to drive amplified therapeutic effects that push the boundary of what conventional antibody therapies can achieve. This collaboration extends our therapeutic innovations while we continue to develop our internal pipeline.”

DualScreen™ Bispecific Discovery Engine

Dualitas’ first-of-its-kind DualScreen discovery engine uniquely enables high-throughput discovery of proximity biology and novel BsAbs that are rapidly optimized into differentiated drug candidates. Whereas traditional BsAb approaches narrowly focus on pre-determined target pairs to realize incremental gains, the DualScreen™ engine functionally screens entire cell surfaces – interrogating the proximity biology of hundreds of thousands of unique bispecific combinations – across a vast range of targets and epitopes to identify BsAb candidates. DualScreen™ technology has discovered powerful cell surface proximity mechanisms and rapidly delivers drug candidates that achieve synergistic activities unattainable by conventional therapeutics.

About Dualitas Therapeutics

Dualitas Therapeutics, Inc. is a biotechnology company pioneering next-generation bispecific antibody therapies for immunology and inflammation (I&I). Dualitas’ portfolio, built from its DualScreen™ discovery engine, includes development candidate DTX-102 in rheumatoid arthritis, DTX-103 in allergic disease and DTX-101 in dermatologic and gastrointestinal autoimmune disease, alongside additional discoveries based on cell-surface proximity biology and novel co-target pairing. While advancing its own pipeline, Dualitas offers a variety of strategic collaboration opportunities to extend the impact of its discovery capabilities, ranging from existing pipeline programs to identifying de novo BsAbs to establishing programs in disease areas beyond I&I. For more information, please visit https://www.dualitastx.com/ and follow us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dualitas-therapeutics-announces-proximity-biology-research-collaboration-with-roche-to-discover-and-develop-novel-bispecific-antibodies-for-ii-diseases-302880473.html

SOURCE Dualitas Therapeutics

Continue Reading

Technology

Four in 10 Gen Z professionals see job hopping as a path to higher pay, according to Robert Half

Published

on

By

46% of Gen Z professionals plan to look for a new job by year-endMore than one quarter of Gen Z professionals say AI pressures are contributing to burnoutGreater workplace flexibility, stronger benefits, and career advancement opportunities are driving Gen Z job searches

TORONTO, Sept. 17, 2026 /CNW/ — Gen Z professionals may be considering a job change to improve their earning potential, according to research from talent solutions and business consulting firm Robert Half. In a recent survey, almost half (46%) say they plan to look for a new job before the end of the year, up from 36% one year ago.

Salary is a major factor behind the shift, as four in 10 Gen Z professionals (41%) believe changing employers could offer greater earning potential. They’re also motivated by stronger perks and benefits, career advancement opportunities, and greater workplace flexibility. In addition, expectations tied to AI adoption may be adding pressure, with more than one-quarter (28%) saying integrating AI into their daily work has led to burnout.

Key findings:

46% of Gen Z professionals plan to look for a new job by year-endOf those looking, 51% want stronger perks and benefits and 44% are looking for greater advancement opportunities46% also worry about keeping their AI skills current41% of Gen Z professionals believe changing employers could offer greater salary potential

What do Gen Z professionals value?

According to the research, many Gen Z professionals are seeking opportunities that better align with their career aspirations, financial goals, and overall workplace expectations. The top benefits and perks that Gen Z workers consider when evaluating offers include:

Flexible work schedules (61%)Dental coverage (60%)Commuter benefits (55%)Free or subsidized meals, snacks, or beverages (55%)Hybrid work options (49%)RRSP or pension savings plans (49%)Mental health coverage (48%)

“Gen Z professionals are entering the workforce during a time of significant change and taking a thoughtful approach to their careers,” said Koula Vasilopoulos, senior managing director, Robert Half, Canada. “Many are considering factors such as higher earning potential, more flexibility and career advancement opportunities, and they are willing to explore new opportunities to find it.”

Gen Z embraces AI but burnout is mounting

Gen Z workers are adapting to a workplace increasingly influenced by AI. Although 73% say they use AI for professional purposes, more than one-quarter (28%) say integrating AI into their daily work has led to burnout, primarily because they:

Have fears over job security if they don’t adopt new tools (45%)Feel pressure to be more productive (29%)Feel overwhelmed by continuous learning requirements (26%)

“While many Gen Z professionals are embracing AI in the workplace, they are also feeling the pressure to keep their skills on pace with rapidly evolving technology and rising productivity expectations,” said Vasilopoulos. “Employers can play an important role by providing ongoing training and support that helps employees build new skills, maximize the benefits of AI, and avoid burnout.”

FAQ:

Why are Gen Z professionals looking for new jobs now?
Gen Z professionals are increasingly exploring new opportunities to find stronger career growth, higher earning potential, and greater flexibility. Many are seeking a new role before the end of the year that offers a clear path to advancement and aligns with their workplace expectations.

Which workplace benefits matter most to Gen Z professionals?
Flexibility remains a key priority, but many Gen Z professionals also place significant value on benefits that support their financial well-being and long-term stability. They’re evaluating the full employee experience, not just salary alone.

How is AI affecting Gen Z employees at work?
While Gen Z has been quick to adopt AI and integrate it into daily work, many are navigating the pressures that come with evolving technology. Expectations around productivity and keeping skills current have contributed to workplace burnout.

What can employers do to attract and retain Gen Z talent?
Employers can strengthen retention by offering clear career development opportunities, competitive compensation, and greater flexible work options. Providing support for AI adoption and ongoing skills development can also help employees feel more confident and engaged.

About the research 
The research is gathered from two surveys developed by Robert Half and conducted by an independent research firm in March and April 2026. The surveys contain responses from more than 300 Gen Z professionals in Canada. 

About Robert Half
Robert Half (NYSE: RHI) is the world’s first and largest specialized talent solutions and business consulting firm, connecting highly skilled job seekers with rewarding opportunities at great companies. We offer contract talent and permanent placement solutions in the fields of finance and accounting, technology, marketing and creative, legal, and administrative and customer support, and we also provide executive search services. Robert Half is the parent company of Protiviti®, a global consulting firm that delivers internal audit, risk, business and technology consulting solutions. Robert Half, including Protiviti, has been named one of the Fortune® Most Admired Companies™, and by Forbes as one of Canada’s Best Recruiting and Temporary Staffing Firms 2026. Explore comprehensive talent solutions, research and insights at RobertHalf.ca.

SOURCE Robert Half Canada Inc.

Continue Reading

Technology

Molecular Devices Expands SoftMax® Pro GxP Software Suite with GLP Mode to Help Laboratories Advance Confidently from Discovery Toward Regulated Compliance

Published

on

By

New microplate reader software helps laboratories apply appropriate controls as workflows evolve from discovery toward more regulated environments

SAN JOSE, Calif., Sept. 17, 2026 /PRNewswire-PRWeb/ — Molecular Devices, a Danaher company and a leading provider of high‑performance life science solutions, today introduced SoftMax® Pro 7.6 GLP Mode, the newest addition to the SoftMax Pro 7.6 GxP Software Suite. Designed to support laboratories at different stages of compliance maturity, the new GLP Mode helps teams strengthen data integrity, traceability, and workflow oversight, creating more defendable records, stronger accountability across users, and greater confidence in their data as compliance expectations evolve, without adding unnecessary complexity. The expanded suite helps laboratories apply the right level of control as their work progresses from development and non-clinical research toward more regulated environments.

By expanding the SoftMax Pro GxP Software Suite with a purpose-built GLP option, laboratories can take the next practical step toward stronger oversight without adding unnecessary complexity.

As biotechnology and pharmaceutical programs advance, laboratories face growing expectations for secure data management, consistent workflow execution, traceable audit trail review, and audit-ready reporting in trusted, controlled software environments. SoftMax Pro 7.6 GLP Mode helps bridge the gap for development-stage laboratories that may not require the extensive infrastructure associated with GMP operations but still need practical governance and oversight tools.

“Customers need compliance solutions that evolve alongside their science, while maintaining consistency across teams, workflows, and operating environments,” said Mary Duseau, President of Molecular Devices. “By expanding the SoftMax Pro GxP Software Suite with a purpose-built GLP option, laboratories can take the next practical step toward stronger oversight without adding unnecessary complexity. This connected approach helps teams standardize workflows, strengthen confidence in their data, and accelerate progress from discovery to impact across organizations and geographies.”

SoftMax Pro 7.6 GLP Mode adds enhanced user management, electronic signatures, audit-ready reporting, and controls that help standardize data management across teams. As part of the broader SoftMax Pro 7.6 GxP Software Suite, the new mode gives biotechnology, pharmaceutical, contract research, and translational research organizations a practical way to increase oversight of plate reader data and support evolving compliance expectations.

Compatible with the full line of SoftMax Pro SpectraMax® microplate readers, the SoftMax Pro 7.6 GxP Software Suite is now available worldwide. Learn more here.

About Molecular Devices

Molecular Devices, a Danaher Company, is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Media Contact

Amy Smith, Molecular Devices, 1 4083344699, amy.smith@moldev.com

View original content:https://www.prweb.com/releases/molecular-devices-expands-softmax-pro-gxp-software-suite-with-glp-mode-to-help-laboratories-advance-confidently-from-discovery-toward-regulated-compliance-302881755.html

SOURCE Molecular Devices

Continue Reading

Technology

Israel Defense Forces, Through the Ministry of Defense’s Directorate of Defense, Research and Development (MAFAT) Recognizes Innoviz Technologies’ LiDAR Capabilities as Suitable for Defense Applications

Published

on

By

In a letter to Innoviz, MAFAT recognizes the maturity, robustness, performance and scalability of Innoviz LiDARs and the precise sensing that can help defense systems, via a range of defense applications, see clearly, act faster, and potentially save lives.

TEL AVIV, Israel, Sept. 17, 2026 /PRNewswire/ — Innoviz Technologies Ltd. (NASDAQ: INVZ) (the “Company” or “Innoviz”), a leading supplier of high-performance, automotive-grade LiDAR sensor platforms for autonomous driving, defense and homeland security, industrial, and smart infrastructure applications, today announced that its existing LiDAR solutions were recognized by the Directorate of Defense Research & Development (DDR&D), known as MAFAT, within the Israel Ministry of Defense, as suitable for defense applications, addressing emerging requirements for defense applications. Innoviz believes its existing, production-proven LiDAR is capable of addressing some of the defense domain’s demanding sensing challenges, with potential applications across counter-UAS, perimeter security, and critical-infrastructure protection.

Drawing on ongoing technical assessments and practical experimentation, MAFAT views the maturity, robustness, scalability, and performance of Innoviz’s LiDAR as having the potential to provide reliable, high-resolution perception in complex operational environments where traditional sensing modalities often face substantial limitations.

MAFAT further notes that Innoviz’s existing solutions address the emerging requirements in next-generation defense applications, pointing to the potential for future deployment across a range of field applications. 

Innoviz believes that recognition by MAFAT, given its worldwide reputation, could help support potential demand for Innoviz’s solutions among certain Western defense customers over time. Following its evaluation and recognition of Innoviz’s capabilities, Innoviz is now well positioned and already delivering its proven LiDAR technology, as announced recently, in support of defense applications.

“We are proud that MAFAT has recognized our LiDAR solutions”, said Omer Keilaf, Founder and CEO of Innoviz. “What we engineered for automotive was never just about cars, but about Physical AI as a whole. Measuring the physical world precisely and reliably and manufacturing that capability at scale is exactly what defense and homeland security applications demand. We designed our LiDAR to perform in harsh real-world conditions, and we are glad to see that same proven capability recognized for its fit across a wide range of defense applications.”

About Innoviz
Innoviz is a leading provider of LiDAR technology, serving as a Tier-1 supplier to the world’s leading automotive manufacturers while extending its existing sensing solutions into defense, homeland security, industrial, and smart infrastructure markets.

Innoviz’s LiDAR sensors and complementary software suite are designed to deliver exceptional range, resolution, and reliability, providing accurate 3D sensing even in harsh weather conditions. Built to meet the automotive industry’s strict standards for performance and safety, Innoviz’s sensors are increasingly supplied for applications that demand precise, real-time spatial awareness and continuous object localization.

Operating across the U.S., Europe, and Asia, Innoviz designs solutions for automotive OEMs, system integrators, municipalities, commercial enterprises, government organizations, and other customers worldwide. Under the Perciz brand, Innoviz offers its existing automotive-grade LiDAR sensors for defense, counter-UAS, perimeter intrusion detection, and homeland security applications. For more information, visit innoviz.tech

About Innoviz Perciz 
Perciz is Innoviz’s dedicated defense and homeland security brand, focused on using Innoviz’s existing LiDAR solutions for defense, homeland security, and critical infrastructure applications. By using Innoviz’s rich data, we believe operators will be able to perceive, understand, and act in the physical world with greater intelligence and precision. Perciz has the ability to support the next-generation defense and homeland security systems designed to address the increasing complexity of modern threats. For more information, visit innoviz.tech/perciz.

Join the discussion: FacebookLinkedInYouTubeX

Media Contact
Media@innoviz-tech.com

Investor Contact
Investors@innoviz-tech.com

Forward Looking Statements

This announcement contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the services and products offered by Innoviz, the anticipated technological capability of Innoviz’s products, including performance under various environmental and operational conditions, the markets in which Innoviz operates, and the Company’s ability to successfully enter and compete in the defense and homeland security markets, and the potential for synergies between the Company’s automotive and defense market activities. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “potential”, “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

Many factors could cause actual future events to differ materially from the forward-looking statements in this announcement, including but not limited to, the ability to implement business plans, forecasts, and other expectations, the ability to achieve broader market adoption of Innoviz’s products and solutions, the risks associated with the defense and homeland security market, including procurement cycles, budgetary constraints and regulatory and export control considerations, the early stage of the Company’s defense and security business, and our expectations regarding the impact of geopolitical developments in the Middle East including the evolving conflict in Israel on our ongoing operations. The foregoing list is not exhaustive. You should carefully consider such risk and the other risks and uncertainties described in Innoviz’s annual report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2026, and in other documents filed by Innoviz from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. The recognition and evaluation referenced in this announcement are preliminary and do not constitute a procurement decision, contractual commitment, or commitment of future funding. There can be no assurances that such recognition will result in definitive agreements, firm orders, payments, or series production, or that volumes, timing, or commercial terms will align with current expectations. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Innoviz assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Innoviz gives no assurance that it will achieve its expectations.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/israel-defense-forces-through-the-ministry-of-defenses-directorate-of-defense-research-and-development-mafat-recognizes-innoviz-technologies-lidar-capabilities-as-suitable-for-defense-applications-302882027.html

SOURCE Innoviz Technologies

Continue Reading

Trending